farmaecFARMAKOEKONOMIKA. Modern Pharmacoeconomics and PharmacoepidemiologyФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология2070-49092070-4933IRBIS LLC10.17749/2070-4909/farmakoekonomika.2025.298farmaec-1232Research ArticleREVIEW ARTICLESОБЗОРНЫЕ ПУБЛИКАЦИИIgA nephropathy: predicting the risks of progressionIgA-нефропатия: прогнозирование рисков прогрессированияhttps://orcid.org/0000-0002-0459-0488КорабельниковД. И.KorabelnikovD. I.

Корабельников Даниил Иванович, к.м.н., доцент

2-я Брестская ул., д. 5, Москва 123056

Daniil I. Korabelnikov, PhD, Assoc. Prof. 

5 2nd Brestskaya Str., Moscow 123056

https://orcid.org/0000-0002-3787-1147МанцаеваМ. Е.MantsaevaM. E.

Манцаева Мария Евгеньевна

2-я Брестская ул., д. 5, Москва 123056

ул. Намёткина, д. 16, корп. 4, Москва 117420

ул. Народного ополчения, д. 35, Москва 123060

Maria E.  Mantsaeva

5 2nd Brestskaya Str., Moscow 123056

16 Nametkina Str., Moscow 117420

35 Narodnogo Opolcheniya Str., Moscow 123060

MariyaMantsaeva@yandex.ruАвтономная некоммерческая организация дополнительного профессионального образования «Московский медикосоциальный институт им. Ф.П. Гааза»РоссияMoscow Haass Medical and Social InstituteRussian FederationАвтономная некоммерческая организация дополнительного профессионального образования «Московский медикосоциальный институт им. Ф.П. Гааза»; Медицинское частное учреждение «Отраслевой клинико-диагностический центр ПАО «Газпром»; Федеральное казенное учреждение здравоохранения «Главный клинический госпиталь Министерства внутренних дел Российской Федерации»РоссияMoscow Haass Medical and Social Institute; Branch Clinical and Diagnostic Center of PJSC Gazprom; Main Clinical Hospital of the Ministry of Internal Affairs of the Russian FederationRussian Federation202506082025182294–303Copyright © Korabelnikov D.I., Mantsaeva M.E., 20252025Корабельников Д.И., Манцаева М.Е.Korabelnikov D.I., Mantsaeva M.E.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacoeconomics.ru/jour/article/view/1232

Immunoglobulin A (IgA) nephropathy is the most common form of chronic glomerulonephritis and one of the leading causes of end-stage renal disease. Currently, the ability to accurately predict the risk of this progression at the individual patient level is limited. This paper analyzes the scientific literature containing research results focused on identifying independent predictors of IgA nephropathy progression risk. According to most studies, variables such as proteinuria, arterial hypertension, and baseline kidney function have a stable and independent association with worse kidney prognosis. Histological changes in kidney biopsy serve as independent predictors. The combination of morphologic and clinical data improves predictive accuracy. To enhance treatment outcomes and long-term prognosis, further research is necessary, including the search for new biomarkers and the development of a universally accepted risk stratification system.

Иммуноглобулин А-нефропатия (англ. immunoglobulin A, IgA) является наиболее распространенной формой хронического гломерулонефрита и одной из ведущих причин терминальной почечной недостаточности. В настоящее время возможности точного прогнозирования риска прогрессирования данной патологии на уровне отдельных пациентов ограничены. В статье проведен анализ научной литературы, содержащей результаты исследований, посвященных определению независимых предикторов риска про грессирования IgA-нефропатии. Согласно результатам большинства исследований такие переменные, как протеинурия, артериальная гипертензия и исходная функция почек, имеют устойчивую и независимую связь с ухудшением почечного прогноза. Гистологические изменения в нефробиоптате выступают как отдельные предикторы. Сочетание морфологических и клинических данных позволяет повысить точность прогнозирования. Для улучшения результатов лечения и отдаленных исходов необходимы дальнейшие исследования, включая поиск новых биомаркеров и разработку общепринятой системы стратификации риска.

иммуноглобулин А-нефропатияпочечный исходриск прогрессированияпредикторы прогрессированияпрогнозмногофакторный анализimmunoglobulin A nephropathyrenal outcomerisk of progressionpredictors of progressionprognosismultivariate analysisReferencesШилов Е.М., Смирнов А.В., Козловская Н.Л. (ред.) Нефрология. Клинические рекомендации. М.: ГЭОТАР-Медиа; 2016: 816 с.Shilov E.M., Smirnov A.V., Kozlovskaya N.L. (Eds) Nephrology. Clinical recommendations. Moscow: GEOTAR-Media; 2016: 816 pp. (in Russ.).Бобкова И.Н., Буланов Н.М., Захарова Е.В. и др. Клинические практические рекомендации KDIGO 2021 по лечению гломерулярных болезней. Нефрология и диализ. 2022; 24 (4): 577–874. https://doi.org/10.28996/2618-9801-2022-4-577-874.Bobkova I.N., Bulanov N.M., Zakharova E.V., et al. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Nephrology and Dialysis. 2022; 24 (4): 577–874 (in Russ.). https://doi.org/10.28996/2618-9801-2022-4-577-874.Schena F.P., Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018; 38 (5): 435–42. https://doi.org/10.1016/j.semnephrol.2018.05.013.Schena F.P., Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018; 38 (5): 435–42. https://doi.org/10.1016/j.semnephrol.2018.05.013.Soares M.F. An update on pathology of IgA nephropathy. J Bras Nefrol. 2016; 38 (4): 435–40. https://doi.org/10.5935/0101-2800.20160069.Soares M.F. An update on pathology of IgA nephropathy. J Bras Nefrol. 2016; 38 (4): 435–40. https://doi.org/10.5935/0101-2800.20160069.Riispere Ž., Laurinavičius A., Kuudeberg A., et al. IgA nephropathy clinicopathologic study following the Oxford classification: progression peculiarities and gender-related differences. Medicina. 2016; 52 (6): 340–8. https://doi.org/10.1016/j.medici.2016.11.003.Riispere Ž., Laurinavičius A., Kuudeberg A., et al. IgA nephropathy clinicopathologic study following the Oxford classification: progression peculiarities and gender-related differences. Medicina. 2016; 52 (6): 340–8. https://doi.org/10.1016/j.medici.2016.11.003.Kiryluk K., Freedberg D.E., Radhakrishnan J., et al. Global incidence of IgA nephropathy by race and ethnicity: a systematic review. Kidney360. 2023; 4 (8): 1112–22. https://doi.org/10.34067/KID.0000000000000165.Kiryluk K., Freedberg D.E., Radhakrishnan J., et al. Global incidence of IgA nephropathy by race and ethnicity: a systematic review. Kidney360. 2023; 4 (8): 1112–22. https://doi.org/10.34067/KID.0000000000000165.Yamada K., Doi S., Nakashima A., et al. Expression of age-related factors during the development of renal damage in patients with IgA nephropathy. Clin Exp Nephrol. 2015; 19 (5): 830–7. https://doi.org/10.1007/s10157-014-1070-2.Yamada K., Doi S., Nakashima A., et al. Expression of age-related factors during the development of renal damage in patients with IgA nephropathy. Clin Exp Nephrol. 2015; 19 (5): 830–7. https://doi.org/10.1007/s10157-014-1070-2.Sato Y., Tsukaguchi H., Higasa K., et al. Positive renal familial history in IgA nephropathy is associated with worse renal outcomes: a singlecenter longitudinal study. BMC Nephrol. 2021; 22 (1): 230. https://doi.org/10.1186/s12882-021-02425-8.Sato Y., Tsukaguchi H., Higasa K., et al. Positive renal familial history in IgA nephropathy is associated with worse renal outcomes: a singlecenter longitudinal study. BMC Nephrol. 2021; 22 (1): 230. https://doi.org/10.1186/s12882-021-02425-8.Barbour S.J., Coppo R., Zhang H., et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019; 179 (7): 942–52. https://doi.org/10.1001/jamainternmed.2019.0600.Barbour S.J., Coppo R., Zhang H., et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019; 179 (7): 942–52. https://doi.org/10.1001/jamainternmed.2019.0600.Coppo R., Troyanov S., Bellur S., et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014; 86 (4): 828–36. https://doi.org/10.1038/ki.2014.63.Coppo R., Troyanov S., Bellur S., et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014; 86 (4): 828–36. https://doi.org/10.1038/ki.2014.63.Mohd R., Mohammad Kazmin N.E., Abdul Cader R., et al. Long term outcome of immunoglobulin A (IgA) nephropathy: a single center experience. PLoS One. 2021; 16 (4): e0249592. https://doi.org/10.1371/journal.pone.0249592.Mohd R., Mohammad Kazmin N.E., Abdul Cader R., et al. Long term outcome of immunoglobulin A (IgA) nephropathy: a single center experience. PLoS One. 2021; 16 (4): e0249592. https://doi.org/10.1371/journal.pone.0249592.Tang C., Chen P., Si F.L., et al. Time-varying proteinuria and progression of IgA nephropathy: a cohort study. Am J Kidney Dis. 2024; 84 (2): 170–8e1. https://doi.org/10.1053/j.ajkd.2023.12.016.Tang C., Chen P., Si F.L., et al. Time-varying proteinuria and progression of IgA nephropathy: a cohort study. Am J Kidney Dis. 2024; 84 (2): 170–8e1. https://doi.org/10.1053/j.ajkd.2023.12.016.Le W., Liang S., Hu Y., et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012; 27 (4): 1479–85. https://doi.org/10.1093/ndt/gfr527.Le W., Liang S., Hu Y., et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012; 27 (4): 1479–85. https://doi.org/10.1093/ndt/gfr527.Li X., Liu Y., Lv J., et al. Progression of IgA nephropathy under current therapy regimen in a Chinese population. Clin J Am Soc Nephrol. 2014; 9 (3): 484–9. https://doi.org/10.2215/CJN.01990213.Li X., Liu Y., Lv J., et al. Progression of IgA nephropathy under current therapy regimen in a Chinese population. Clin J Am Soc Nephrol. 2014; 9 (3): 484–9. https://doi.org/10.2215/CJN.01990213.Shirai S., Yasuda T., Kumagai H., et al. Prognostic factors of IgA nephropathy presenting with mild proteinuria at the time of diagnosis (a multicenter cohort study). Clin Exp Nephrol. 2023; 27 (4): 340–8. https://doi.org/10.1007/s10157-023-02316-2.Shirai S., Yasuda T., Kumagai H., et al. Prognostic factors of IgA nephropathy presenting with mild proteinuria at the time of diagnosis (a multicenter cohort study). Clin Exp Nephrol. 2023; 27 (4): 340–8. https://doi.org/10.1007/s10157-023-02316-2.Berthoux F., Mohey H., Laurent B., et al. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011; 22 (4): 752–61. https://doi.org/10.1681/ASN.2010040355.Berthoux F., Mohey H., Laurent B., et al. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011; 22 (4): 752–61. https://doi.org/10.1681/ASN.2010040355.Soleymanian T., Najafi I., Salimi B.H., Broomand B. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in Iran. Ren Fail. 2011; 33 (6): 572–7. https://doi.org/10.3109/0886022X.2011.585001.Soleymanian T., Najafi I., Salimi B.H., Broomand B. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in Iran. Ren Fail. 2011; 33 (6): 572–7. https://doi.org/10.3109/0886022X.2011.585001.Wakai K., Kawamura T., Endoh M., et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant. 2006; 21 (10): 2800–8. https://doi.org/10.1093/ndt/gfl342.Wakai K., Kawamura T., Endoh M., et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant. 2006; 21 (10): 2800–8. https://doi.org/10.1093/ndt/gfl342.Geddes C., Rauta V., Gronhagen-Riska C., et al. A tricontinental view of IgA nephropathy. Nephrol Dial Transplant. 2003; 18 (8): 1541–8. https://doi.org/10.1093/ndt/gfg207.Geddes C., Rauta V., Gronhagen-Riska C., et al. A tricontinental view of IgA nephropathy. Nephrol Dial Transplant. 2003; 18 (8): 1541–8. https://doi.org/10.1093/ndt/gfg207.Chen D., Liu J., Duan S., et al. Clinicopathological features to predict progression of IgA nephropathy with mild proteinuria. Kidney Blood Press Res. 2018; 43 (2): 318–28. https://doi.org/10.1159/000487901.Chen D., Liu J., Duan S., et al. Clinicopathological features to predict progression of IgA nephropathy with mild proteinuria. Kidney Blood Press Res. 2018; 43 (2): 318–28. https://doi.org/10.1159/000487901.Weng M., Lin J., Chen Y., et al. Time-averaged hematuria as a prognostic indicator of renal outcome in patients with IgA nephropathy. J Clin Med. 2022; 11 (22): 6785. https://doi.org/10.3390/jcm11226785.Weng M., Lin J., Chen Y., et al. Time-averaged hematuria as a prognostic indicator of renal outcome in patients with IgA nephropathy. J Clin Med. 2022; 11 (22): 6785. https://doi.org/10.3390/jcm11226785.Sevillano A., Gutiérrez E., Yuste C., et al. Remission of hematuria improves renal survival in IgA nephropathy. J Am Soc Nephrol. 2017; 28 (10): 3089–99. https://doi.org/10.1681/ASN.2017010108.Sevillano A., Gutiérrez E., Yuste C., et al. Remission of hematuria improves renal survival in IgA nephropathy. J Am Soc Nephrol. 2017; 28 (10): 3089–99. https://doi.org/10.1681/ASN.2017010108.Добронравов В.А. Мужецкая Т.О., Лин Д.И., Кочоян З.Ш. Иммуноглобулин А-нефропатия в российской популяции: клиникоморфологическая презентация и отдаленный прогноз. Нефрология. 2019; 23 (6): 45–60. https://doi.org/10.36485/1561-6274-2019-23645-60.Dobronravov V.A., Muzhetskaya T.O., Lin D.I., Kochoyan Z.Sh. Immunoglobulin A-nephropathy in Russian population: clinical and morphological presentation and long-term prognosis. Nephrology (Saint-Petersburg). 2019; 23 (6): 45–60 (in Russ.). https://doi.org/10.36485/1561-6274-2019-236-45-60.Tanaka S., Ninomiya T., Katafuchi R., et al. Development and validation of a prediction rule using the Oxford classification in IgA nephropathy. Clin J Am Soc Nephrol. 2013; 8 (12): 2082–90. https://doi.org/10.2215/CJN.03480413.Tanaka S., Ninomiya T., Katafuchi R., et al. Development and validation of a prediction rule using the Oxford classification in IgA nephropathy. Clin J Am Soc Nephrol. 2013; 8 (12): 2082–90. https://doi.org/10.2215/CJN.03480413.Heybeli C., Oktan M.A, Yıldız S., et al. Clinical significance of mesangial IgM deposition in patients with IgA nephropathy. Clin Exp Nephrol. 2019; 23 (3): 371–9. https://doi.org/10.1007/s10157-0181651-6.Heybeli C., Oktan M.A, Yıldız S., et al. Clinical significance of mesangial IgM deposition in patients with IgA nephropathy. Clin Exp Nephrol. 2019; 23 (3): 371–9. https://doi.org/10.1007/s10157-0181651-6.Zeng C.H., Le W., Ni Z., et al. A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult chinese patients. Am J Kidney Dis. 2012; 60 (5): 812–20. https://doi.org/10.1053/j.ajkd.2012.06.011.Zeng C.H., Le W., Ni Z., et al. A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult chinese patients. Am J Kidney Dis. 2012; 60 (5): 812–20. https://doi.org/10.1053/j.ajkd.2012.06.011.Walsh M., Sar A., Lee D., et al. Histopathologic features aid in predicting risk for progression of IgA nephropathy. Clin J Am Soc Nephrol. 2010; 5 (3): 425-30. https://doi.org/10.2215/CJN.06530909.Walsh M., Sar A., Lee D., et al. Histopathologic features aid in predicting risk for progression of IgA nephropathy. Clin J Am Soc Nephrol. 2010; 5 (3): 425-30. https://doi.org/10.2215/CJN.06530909.Manno C., Strippoli G.F, D'Altri C., et al. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis. 2007; 49 (6): 763–75. https://doi.org/10.1053/j.ajkd.2007.03.013.Manno C., Strippoli G.F, D'Altri C., et al. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis. 2007; 49 (6): 763–75. https://doi.org/10.1053/j.ajkd.2007.03.013.Yau T., Korbet M., Schwartz M.M., et al. The Oxford classification of IgA nephropathy: a retrospective analysis. Am J Nephrol. 2011; 34 (5): 435–44. https://doi.org/10.1159/000332223.Yau T., Korbet M., Schwartz M.M., et al. The Oxford classification of IgA nephropathy: a retrospective analysis. Am J Nephrol. 2011; 34 (5): 435–44. https://doi.org/10.1159/000332223.Lv J., Shi S., Xu D., et al. Evaluation of the Oxford classification of IgA nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2013; 62 (5): 891–9. https://doi.org/10.1053/j.ajkd.2013.04.021.Lv J., Shi S., Xu D., et al. Evaluation of the Oxford classification of IgA nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2013; 62 (5): 891–9. https://doi.org/10.1053/j.ajkd.2013.04.021.Alamartine E., Sauron С., Laurent B., et al. Use of the Oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol. 2011; 6 (10): 2384–8. https://doi.org/10.2215/CJN.01170211.Alamartine E., Sauron С., Laurent B., et al. Use of the Oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol. 2011; 6 (10): 2384–8. https://doi.org/10.2215/CJN.01170211.Reich H.N., Troyanov S., Scholey J.W., et al. Toronto Glomerulonephritis Registry: remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007; 18 (12): 3177– 83. https://doi.org/10.1681/ASN.2007050526.Reich H.N., Troyanov S., Scholey J.W., et al. Toronto Glomerulonephritis Registry: remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007; 18 (12): 3177– 83. https://doi.org/10.1681/ASN.2007050526.Bobart S.A., Alexander M.P., Shawwa K., et al. The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy. Nephrol Dial Transplant. 2021; 36 (5): 840–7. https://doi.org/10.1093/ndt/gfz267.Bobart S.A., Alexander M.P., Shawwa K., et al. The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy. Nephrol Dial Transplant. 2021; 36 (5): 840–7. https://doi.org/10.1093/ndt/gfz267.Schimpf J.I., Klein T., Fitzner C., et al. Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores). BMC Nephrol. 2018; 19 (1): 328. https://doi.org/10.1186/s12882-018-1128-6.Schimpf J.I., Klein T., Fitzner C., et al. Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores). BMC Nephrol. 2018; 19 (1): 328. https://doi.org/10.1186/s12882-018-1128-6.Alamartine E., Sabatier J.C., Berthoux F.C. Comparison of pathological lesions on repeated renal biopsies in 73 patients with primary IgA glomerulonephritis: value of quantitative scoring and approach to final prognosis. Clin Nephrol. 1990; 34 (2): 45–51.Alamartine E., Sabatier J.C., Berthoux F.C. Comparison of pathological lesions on repeated renal biopsies in 73 patients with primary IgA glomerulonephritis: value of quantitative scoring and approach to final prognosis. Clin Nephrol. 1990; 34 (2): 45–51.Sakai H., Abe K., Kobayashi Y., et al. Clinical guidelines of IgA nephropathy. Nihon Jinzo Gakkai Shi. 1990; 37 (8): 417–21.Sakai H., Abe K., Kobayashi Y., et al. Clinical guidelines of IgA nephropathy. Nihon Jinzo Gakkai Shi. 1990; 37 (8): 417–21.Lee S.M.K., Rao V.M., Franklin W.A., et al. IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol. 1982; 13 (4): 314–22. https://doi.org/10.1016/s0046-8177(82)80221-9.Lee S.M.K., Rao V.M., Franklin W.A., et al. IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol. 1982; 13 (4): 314–22. https://doi.org/10.1016/s0046-8177(82)80221-9.Thompson A., Carroll K.A., Inker L., et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019; 14 (3): 469–81. https://doi.org/10.2215/CJN.08600718.Thompson A., Carroll K.A., Inker L., et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019; 14 (3): 469–81. https://doi.org/10.2215/CJN.08600718.Cravedi P., Remuzzi G. Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. Br J Clin Pharmacol. 2013; 76 (4): 516–23. https://doi.org/10.1111/bcp.12104.Cravedi P., Remuzzi G. Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. Br J Clin Pharmacol. 2013; 76 (4): 516–23. https://doi.org/10.1111/bcp.12104.Huang Z., Wen Q., Zhou S.F., Yu X.Q. Differential chemokine expression in tubular cells in response to urinary proteins from patients with nephrotic syndrome. Cytokine. 2008; 42 (2): 222–33. https://doi.org/10.1016/j.cyto.2008.02.005.Huang Z., Wen Q., Zhou S.F., Yu X.Q. Differential chemokine expression in tubular cells in response to urinary proteins from patients with nephrotic syndrome. Cytokine. 2008; 42 (2): 222–33. https://doi.org/10.1016/j.cyto.2008.02.005.Barbour S., Reich H. An update on predicting renal progression in IgA nephropathy. Curr Opin Nephrol Hypertens. 2018; 27 (3): 214–20. https://doi.org/10.1097/MNH.0000000000000405.Barbour S., Reich H. An update on predicting renal progression in IgA nephropathy. Curr Opin Nephrol Hypertens. 2018; 27 (3): 214–20. https://doi.org/10.1097/MNH.0000000000000405.Coppo R., D’Amico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005; 18 (5): 503–12.Coppo R., D’Amico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005; 18 (5): 503–12.Roberts I.S., Cook H.T., Troyanov S., et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009; 76 (5): 546–56. https://doi.org/10.1038/ki.2009.168.Roberts I.S., Cook H.T., Troyanov S., et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009; 76 (5): 546–56. https://doi.org/10.1038/ki.2009.168.

The authors declare that there are no conflicts of interest present.